https://www.marketscreener.com/quote/stock/HORIZON-THERAPEUTICS-PUBL-18100076/news/Q32-Bio-and-Horizon-Therapeutics-plc-Announce-Dosing-of-First-Patient-in-Phase-2-Trial-of-Bempikibar-44834479/?utm_source=telegram&utm_medium=social&utm_campaign=share